Supernus Pharmaceuticals SUPN Payment For Contingent Consideration Liability Operating Activities
Payment For Contingent Consideration Liability Operating Activities at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's payment for contingent consideration liability operating activities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's payment for contingent consideration liability operating activities?
- Supernus Pharmaceuticals (SUPN) reported payment for contingent consideration liability operating activities of $0 in Q1 2026.
- How has Supernus Pharmaceuticals's payment for contingent consideration liability operating activities changed year-over-year?
- Supernus Pharmaceuticals's payment for contingent consideration liability operating activities decreased by 100.0% year-over-year, from $4.9M to $0.
- What does payment for contingent consideration liability operating activities mean?
- This represents the actual cash outflow made to settle liabilities associated with performance-based earn-outs from previous business acquisitions. Unlike non-cash fair value adjustments, this reflects the realized cash cost of growth strategies. It helps investors understand the long-term cash obligations tied to inorganic expansion.